+++ Bester Zertifikate-Anbieter bestätigt 🏆 15. Gesamtsieg für Raiffeisen Centrobank beim Zertifikate Award Austria +++-w-
26.09.2021 02:33

Advisory - One lot of the hypoglycemia treatment Glucagon recalled as it may pose serious health risks

Folgen
Werbung

OTTAWA, Sept. 25, 2021 /CNW/ -

Summary

Product: Glucagon (DIN 02243297, lot D239382A, expiry May 10, 2022)

Issue: Eli Lilly Canada Inc. is recalling one lot of Glucagon, following a complaint that a vial from this lot was found to be in liquid form instead of powder form. Glucagon normally comes in a powder form with accompanying diluting solution and should be used immediately after mixing.

What to do: Do not use product from this lot. Call 9-1-1 immediately if you or a family member, including children, have taken this product and are experiencing medical issues, such as hypoglycemia (low blood sugar) or seizures. Consult with your doctor or pharmacist if you have any questions or concerns about the product you are taking.

Issue

Eli Lilly Canada Inc. is recalling one lot of Glucagon (D239382A, expiry May 10, 2022), following a complaint that a vial from this lot was found to be in liquid form rather than powder form. Glucagon normally comes in a powder form with accompanying diluting solution, and should be used immediately after mixing. Other vials in the lot may be affected.

Vials from the affected lot may not work as intended in treating patients with hypoglycemia (low blood sugar) resulting in persisting hypoglycemia. It could also cause other serious health consequences, such as unconsciousness and seizures.

Glucagon is a prescription drug administered by injection for the emergency treatment of severe hypoglycemia (unconsciousness due to low blood sugar), which may occur in diabetic patients (children and adults) treated with insulin.

Health Canada is monitoring the effectiveness of the company's recall and the implementation of any necessary corrective and preventative actions.

What consumers should do

  • Call 9-1-1 immediately if you or your child have taken this product and are experiencing medical issues, such as hypoglycemia or seizures.
  • Do not use Glucagon from the Lot D239382A.
  • Contact Eli Lilly Canada Inc. at 1-888-545-5972 if you have questions about the recall.
  • Report any health product-related adverse reactions or complaints to Health Canada.

Affected products

Company

Product Name/Active Pharmaceutical Ingredient (API)

DIN

Lot

Expiry

Eli Lilly

Glucagon

02243297

D239382A

May 10, 2022

Photos  

Également disponible en français

SOURCE Health Canada

Jetzt kostenlos anmelden!

Welche Megatrends werden die Märkte der Zukunft beherrschen und wie können Investoren die höchsten Renditen erwirtschaften? Im Online-Seminar heute um 18 Uhr gibt Star-Investor Jan Beckers seinen Ausblick auf die wichtigsten Technologien der Zukunft.
Jetzt kostenlos anmelden!
Werbung
Werbung
Werbung
Werbung
Börse Stuttgart Anlegerclub
Werbung

Heute im Fokus

DAX gibt nach -- Valneva-Aktie mit Kursfeuerwerk nach positiven Impfstoffdaten -- TeamViewer sucht neuen CFO -- Siemens, Bitcoin-ETF, Tesla, VW, BVB, Halbleiterwerte im Fokus

Inflationssorgen und Renditen treiben Bankentitel weiter an. Dieselpreis steigt auf Rekordhoch. Abstufung belastet Covestro. Hannover Rück und Munich Re erwartet steigende Preise für Rückversicherungsschutz. Stellantis und LG Energy wollen Batteriefabrik bauen. Berenberg hebt Kursziel für RATIONAL. Philips: Umsatz sinkt etwas stärker als erwartet.

Umfrage

Wo steht der DAX zum Jahresende?

finanzen.net zero
finanzen.net zero

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln